Studies: AstraZeneca, Boehringer drugs beat older blood thinners

08/30/2009 | Los Angeles Times (tiered subscription model)

AstraZeneca's Brilinta and Boehringer Ingelheim's Pradaxa outperformed blood thinners Plavix and warfarin in reducing the risk of clots, heart attack, stroke and death, according to studies presented at the European Society of Cardiology Congress in Spain. AstraZeneca is awaiting FDA approval for Brilinta, while Boehringer sells Pradaxa in 40 countries.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Healthcare Compliance Manager
Ernst & Young
Multiple Locations, SL_Multiple Locations
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Director, Health Plan Administration, Payor Relations and Contracting
St. Charles Health System
Bend, OR
Director, Health Plan Administration, Payor Relations and Contracting
St. Charles Health System
Bend, OR
Compliance Sr Mgr
Amgen
Thousand Oaks, CA